Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

Table 1

Model features.

Patients	50,000
Maximum treatment period with belimumab	10 years
Maximum effect related to belimumab	Lifetime
Subgroup	Patient with low complement and anti-dsDNA
Responder rule	Reduction SELENA-SLEDAI ≥ 4 at 24th week
Natural history model	JH-AMS* forced in, involvement removed
Long term disease activity model	Adjusted natural history models (NHM)
One-year steroid model	NHM

*Johns Hopkins University (JH) Adjusted Mean SLEDAI (AMS).